Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Hemostasis in Pediatric Cardiac Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy and Antiphospholipid Syndrome

    Research output: Contribution to journalReviewResearchpeer-review

  3. Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of Anabolic-Androgenic Steroid Abuse on the Contact Activation System

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mineralocorticoid receptor antagonist improves cardiac structure in Type 2 Diabetes: Data from the MIRAD Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Serum insulin-like factor 3 levels are reduced in former androgen users suggesting impaired Leydig cell capacity

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Abuse of anabolic-androgenic steroids (AASs) is suspected to increase the risk of cardiovascular disease (CVD) and cardiovascular mortality in otherwise healthy individuals. AAS abuse may increase the incidence of CVD by altering the hemostatic balance toward a procoagulant state. Studies on the effect of AAS abuse on the fibrinolytic system, however, have either demonstrated a profibrinolytic effect or no effect of AAS abuse, but the overall effect of AAS on fibrinolysis has not been addressed so far. This cross-sectional study investigated the effect of AAS on fibrin clot lysis, fibrin structure, and the hemostatic proteins, potentially affecting these measures in current and former AAS abusers and healthy age-matched controls. The study population consisted of 37 current and 33 former AAS abusers, along with 30 healthy age-matched controls. Fibrin clot lysis, fibrin structure properties, fibrinogen, coagulation factor XIII (FXIII) plasminogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined. Fibrin clot lysis was significantly reduced in participants abusing AAS compared with former abusers and controls (p < 0.001). Plasma fibrinogen, plasminogen, and plasmin inhibitor were significantly increased in current abusers (p < 0.05). No significant differences were observed with respect to measures of fibrin structure properties, PAI-1, and TAFI (p > 0.05). In conclusion, AAS abuse depresses fibrin clot lysis. This effect is not associated with alterations in fibrin structure but is rather caused by increased plasma concentrations of fibrinogen, FXIII, and plasmin inhibitor. These findings suggest that AAS abuse may be associated with increased thrombotic disease.

Original languageEnglish
JournalSeminars in Thrombosis and Hemostasis
Volume47
Issue number1
Pages (from-to)11-17
Number of pages7
ISSN0094-6176
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • anabolic-androgenic steroids, fibrinolysis, fibrin clot structure, coagulation

ID: 61433966